References to Primary Literature
- RUBANYI GM, POLOKOFF MA: Endothelines: molecularbiology, biochemistry, pharmacology, physiology and pathophysiology. PharmacoL Rev. (1994) 46:325–415.
- TAMIRISA P, FRISHMAN WH, KUMAR A: Endothelin andendothelin antagonism: roles in cardiovascular health and disease. Amer. Heart J. (1995) 130:601–610.
- LEVIN ER: Endothellns. New Eng. J. Med. (1995) 333:356–363.
- MORELAND S: Endothelin receptor antagonists: a brief review. Can. J. Physiol. Pharmacol. (1994) 72:1469–1471.
- WARNER TD: Endothelin receptor antagonists. Cardiovasc. Drug Rev. (1994) 12:105–122.
- XU D, EMOTO N, GIAID A, SLAUGHTER C, KAW S, DEWIT D, YANAGISAWA M: ECE-1: A membrane-bound metallo-protease that catalyses the proteolytic activation of big endothelin-1. Cell (1994) 78:473–485.
- SCHMIDT M, KR0GER B, JACOB E, SEULBERGER II, SUBK-OWSKI T, 011ER R, MEYER T, SCHMALZING G, HILLEN H: Molecular characterization of human and bovine en-dothelin converting enzyme (ECE-1). FEBS Letts. (1994) 356:238–243.
References to Patent Literature
- SCHERING CORP., US5208236 (1992).